A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 5-6, 2014, Pages 406-413

  Bozik, Michael E ^a   Mitsumoto, Hiroshi ^b   Brooks, Benjamin R ^c   Rudnicki, Stacy A ^d   Moore, Dan H ^e   Zhang, Bing ^f   Ludolph, Albert ^g   Cudkowicz, Merit E ^h   Van Den Berg, Leonard H ⁱ   Mather, James ^a   Petzinger, Thomas ^a   Archibald, Donald ^a  

^a SAB: Knopp Biosciences LLC   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Calico Computing   (United States)

^f MacroStat Inc   (United States)

^g UNIVERSITY OF ULM   (Germany)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biomarker; Clinical trials; Mitochondria; Risk; Therapy

Indexed keywords

CREATININE; DEXPRAMIPEXOLE; PLACEBO; RILUZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PROPRANOLOL;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL LABORATORY; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG USE; HUMAN; LABORATORY TEST; MORTALITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION AND POPULATION RELATED PHENOMENA; POST HOC ANALYSIS; PRIORITY JOURNAL; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS, PHASE II AS TOPIC; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROPRANOLOL; RILUZOLE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84906334415     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.943672     Document Type: Article

References (36)

1. Cudkowicz ME, Van Den Berg LH, Shefner J, Mitsumoto H, Mora J, Ludolph A, et al. Dexpramipexole in amyotrophic lateral sclerosis: Results of the randomized, double-blind, placebo-controlled phase III EMPOWER trial. Lancet Neurol. 2013; 12: 1059-67
2. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011; 17: 1652-6
3. Rilutek ̊ (riluzole) Tablets Description: H ttp: //products. sanofi.us/rilutek/rilutek.pdf
4. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009; 10: 310-23
5. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, Van Belle G. Prognosis in amyotrophic lateral sclerosis: A population based study. Neurology. 2003; 60: 813-9
6. Scotton W J, Scott K M, Moore D H, Almedom L, Wijesekera LC, Jannsen A, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012; 13: 502-8
7. Ratti E, Berry JD, Atassi N, Shui A, Hayden D, Schoenfeld D, et al. Predictors of outcomes in amyotrophic lateral sclerosis. Neurology. 2014; 82: P2. 076
8. Turner MR, Kiernan MC, Leigh N, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009; 8: 94-109
9. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler. 2005; 6: 37-44
10. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013; 12: 310-22
11. Ravits J, Appel SH, Baloh R, Barohn R, Brooks BR, Elman L, et al. Deciperhing amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(Suppl 1): 5-18
12. Berry JD, Miller R, Moore DH, Cudkowicz ME, Van Den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 162-8
13. Finkelstein D M, Schoenfeld D A. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999; 18: 1341-54
14. Lawton K A, Cudkowicz M E, Brown M V, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012; 13: 110-8
15. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013; 14: 248-64
16. Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, et al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14(Suppl 1): 53-61
17. Sorenson E J, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF 1 is not beneficial in two-year ALS trial. Neurology. 2008; 71: 1770-5
18. Shefner J M. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008; 19: 495-508
19. Cudkowicz M E, Katz J, Moore D H, O'Neill G, Glass J D, Mitsumoto H, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11: 259-65
20. Mitsumoto H, Gordon P, Kaufmann P, Gooch C L, Przedborski S, Rowland LP. Randomized control trials in ALS: Lessons learned. Amyotroph Lateral Scler. 2004; 5 (Suppl 1): 8-13
21. U .S. Department of Health and Human Services. Guidance for Industry, ' Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products' (Draft Guidance): Http: //www.fda.gov/downloads/ Drugs/GuidanceCompliance RegulatoryInformation/GuidaGuid/ UCM332181.pdf
22. UKMND-LiCALS Study Group, Morrison K E, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase III multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013; 12: 339-45
23. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al; TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007; 69: 776-84
24. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. Lancet Neurol. 2007; 6: 1045-53
25. Berry J D, Shefner J M, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, et al; Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013; 8: E61177
26. Cudkowicz M, Shefner J, NEALS Consortium. Stage III clinical trial of ceftriaxone in subjects with ALS. Neurology. 2013; 80: S36.001
27. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: A population based study in southern Italy. Eur J Neurol. 2007; 14: 262-8
28. Meininger V, Bensimon G, Bradley W R, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials. Amyotroph Lateral Scler. 2004; 5: 107-17
29. Meininger V, Asselain B, Guillet P, Leigh P N, Ludolph A, Lacomblez L, et al; Pentoxifylline European Group. Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial. Neurology. 2006; 66: 88-92
30. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al; CONFIRM Study Investigators. Placebocontrolled phase III study of oral BG-12 or glatiramer in multiple sclerosis. NEJM. 2012; 367: 1087-97
31. Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, et al; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of the double-blind, randomized, placebocontrolled FREEDOMS study. Lancet Neurol. 2012; 11: 420-8
32. GioVannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, et al; CLARITY study group. Sustained disease-Activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post hoc and subgroup analysis. Lancet Neurol. 2011; 10: 329-37
33. Sun X, Briel M, Busse JW, Akl EA, You JJ, Mejza F, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): A study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009; 10: 101
34. Lagakos SW. The challenge of subgroup analyses: Reporting without distorting. NEJM. 2006; 354: 1667-9
35. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: Reporting of subgroup analyses in clinical trials. NEJM. 2007; 357: 2189-94
36. Rothwell PM. Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation. Lancet. 2005; 365: 176-86